- ►diabetesjournals.org A Vella, P Shah, R Basu, A Basu, M Camilleri … - Diabetes, 2001 - Am Diabetes Assoc In vitro studies indicate that glucagon-like peptide-1(7-36)-amide (GLP-1) can
enhance hepatic glucose uptake. To determine whether GLP-1 increases splanchnic
glucose uptake in humans, we studied seven subjects with type 1 diabetes on ... Cited by 42 - Related articles - BL Direct - All 5 versions
A Vella, P Shah, R Basu, A Basu, JJ Holst, RA … - DIABETES-NEW YORK-, 2000 - Am Diabetes Assoc Although it is well established that glucagon-like pep- tide 1(7-36) amide
(GLP-1) is a potent stimulator of insulin secretion, its effects on insulin
action and glu- cose effectiveness are less clear. To determine whether ... Cited by 81 - Related articles - BL Direct - All 5 versions
A Vella, P Shah, A Reed, A Adkins, R Basu, R … - Diabetologia, 2002 - Springer Aims/hypothesis. The aim of this study was to determine whether rapid conversion
to inactive and potentially an- tagonistic peptides could alter the response to
GLP-1. Methods. We evaluated the ability of exendin-4, a GLP-1 analogue ... Cited by 41 - Related articles - BL Direct - All 4 versions
- ►endojournals.org AS Ryan, JM Egan, JF Habener, D Elahi - Journal of Clinical Endocrinology & Metabolism, 1998 - Endocrine Soc Glucagon-like peptide-1 (GLP-1) is an intestinal insulinotropic hormone that
augments insulin secretion in response to meals and lowers blood glucose levels
in both type 1 and type 2 diabetic subjects. It has been proposed that a ... Cited by 55 - Related articles - BL Direct - All 5 versions
L Ørskov, JJ Holst, J Møller, C Ørskov, N … - Diabetologia, 1996 - Springer Summary Previous studies have suggested that gluca- gon-like peptide-1 (GLP-1)
(7-36 amide) may have the direct effect of increasing insulin sensitivity in
healthy man. To evaluate this hypothesis we infused GLP-1 in seven lean ... Cited by 72 - Related articles - BL Direct - All 4 versions
EJ Freyse, S Knospe, T Becher, O El Hag, B … - Metabolism, 1999 - Elsevier A pharmacological concentration of glucagon-like peptide-1 (GLP-1) in the
insulin-deficient state clearly decreases the blood glucose level. Therefore,
this study was designed to evaluate a putatively relevant effect of the ... Cited by 11 - Related articles - BL Direct - All 9 versions
GS Meneilly, CHS McIntosh, RA Pederson, JF … - Diabetes Care, 2001 - Am Diabetes Assoc An important cause of elevated glucose levels in elderly patients with diabetes
is an alteration in non–insulin-mediated glucose uptake (NIMGU). Glucagon-like
peptide 1 (GLP-1) is an intestinal insulinotropic hormone. It has been ... Cited by 61 - Related articles - BL Direct - All 5 versions
JM Egan, C Montrose-Rafizadeh, Y Wang, M … - Endocrinology, 1994 - Endocrine Soc I NCRETINS are hormones released from epithelial cells in the gastrointestinal
tract which enhance insulin secretion in response to food. They account, at
least in part, for the enhanced secretory effect associated with enteral ... Cited by 61 - Related articles - BL Direct - All 3 versions
A Shalev, R Ninnis, U Keller - Hormone research, 2000 - content.karger.com Glucagon-like peptide 1 (GLP-1) is known to stimulate insulin secretion and
biosynthesis, but has also been shown to decrease insulin requirements in type 1
diabetic subjects suggesting insulin-independent effects. To assess whether ... Cited by 11 - Related articles - BL Direct - All 6 versions
GS Meneilly, CHS McIntosh, RA Pederson, JF … - Journals of Gerontology Series A: Biological and …, 2001 - Geron Soc America Results. Glucose values were similar between the control and GLP-1 infusion
studies. 120- to 180-minute insulin values appeared to be higher during the
GLP-1 infusion study (control, 795 ± 63 pmol/l; GLP-1, 1140 ± 275 pmol/l; ... Cited by 22 - Related articles - All 2 versions
